Teva acquires BioXcel’s BXCL501, under FDA review for at-home agitation use; Rumi Therapeutics gains an option on Enthorin’s Fragile X PDE2 inhibitor.
News|Articles|November 12, 2025
DSCSA in the Warehouse: Implications, Opportunities and Best Practices
Author(s) Tecsys
DSCSA compliance is only the beginning. Is your warehouse ready for the challenges it brings? Without the right strategies in place, compliance can create bottlenecks, delay shipments, and lead to costly disruptions. But with the right approach, it’s an opportunity to optimize your warehouse for long-term success. This playbook helps you turn compliance into a competitive edge. By adopting best practices beyond serialization and traceability, you can safeguard your operations, protect your reputation, and enhance patient safety.
Related to this article
Brox.AI’s Hamish Brocklebank on the three approaches to digital twins in pharma — and why only one-to-one clones of real individuals deliver true accuracy.
Shionogi’s Dr. Draica on how XOCOVA blocks viral replication between exposure and symptoms — and why it works even with prior immunity.
Phagenyx’s Chad Hoskins on why AHA/ASA guideline inclusion gives stroke teams a basis to use PES earlier — and what the evidence shows.
Bristol Myers Squibb discloses a patient death in its Phase I CAR-T multiple sclerosis trial, Pathos AI launches multi-year collaborations with Bristol Myers Squibb and Tempus AI to advance Alzheimer’s drug development, and health economist Dr. Nadine Zawadzki speaks with The Ron Lanton Report on how value is defined across healthcare.
Pfizer’s talazoparib-enzalutamide combination moves to earlier line in prostate cancer, with eligibility tied to genetic testing and immature survival data.
Bristol Myers Squibb discloses results from it's Phase I Breakfree-2 trial of CAR-T therapy zola-cel for multiple sclerosis.
Pathos AI launches multi-year collaborations to build an AI-driven dataset for Alzheimer’s and other neurological diseases.
Trending on PharmExec
1
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
2
FDA Extends Talzenna-Xtandi to Hormone-Sensitive Prostate Cancer
3
Pathos Ai Enters Drug Development Collaboration with Bristol Myers Squibb and Tempus Ai
4
Roundup: Teva Acquires BXCL501 for $57.5 Million Upfront, Rumi Therapeutics Enters Option Agreement for Fragile X PDE2 Inhibitor From Enthorin
5